Molecular Partners Ag (MOLN) Return on Sales (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Return on Sales of 0.01% for Q1 2026, little changed year-over-year from 0.01% in Q1 2025, and down 100.07% quarter-over-quarter from 14.39% in Q4 2025.
Molecular Partners Ag (MOLN) Return on Sales (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Return on Sales for 7 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Sales changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 220.36% (up 22036.0% YoY), while the FY2025 annual figure was 11267.13%, up 9781287.0% from the prior year.
- Return on Sales fell to 0.01% in Q1 2026 per MOLN's latest filing, from 14.39% in the prior quarter.
- Across five years, Return on Sales topped out at 109.76% in Q4 2024 and bottomed at 97.24% in Q2 2024.
- Historically, Return on Sales has averaged 1.55% across 5 years, with a median of 0.01% in 2026.
- On a YoY basis, Return on Sales climbed as much as 10985 bps in 2024 and fell as far as 9686 bps in 2024.
- Molecular Partners Ag's Return on Sales stood at 0.01% in 2022, then sank by 1207 bps to 0.09% in 2023, then soared by 120828 bps to 109.76% in 2024, then tumbled by 87 bps to 14.39% in 2025, then tumbled by 100 bps to 0.01% in 2026.
- Business Quant data shows MOLN's Return on Sales at 0.01% in Q1 2026, 14.39% in Q4 2025, and 0.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 0.00% |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | 14.39% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | 109.76% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | -97.24% |
| Mar 31, 2024 | -0.04% |
| Dec 31, 2023 | -0.09% |
| Sep 30, 2023 | -0.05% |
| Jun 30, 2023 | -0.39% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.01% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | -0.03% |
| Jun 30, 2021 | 0.00% |